NEUROCRINE
Live / Applied — Statement of use — registration review complete (as of 17 Aug 2026)
What this means for you
Not registered yet, but its 21 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98978962
- Mark type
- Stylized text
- Filed
- 21 Sept 2023
- Published for opposition
- 18 Jun 2024
- Attorney of record
- Allison Strickland Ricketts
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment of endocrine, hormonal, and genetic diseases, disorders, and conditions; Pharmaceutical preparations for human use for the treatment of rare and orphan diseases, disorders, and conditions, namely, congenital adrenal hyperplasia
Owner
- Neurocrine Biosciences, Inc., San Diego, CA, US
- Neurocrine Biosciences, Inc., San Diego, CA, US
Prosecution history
- 08 Sept 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 08 Sept 2026 — REGISTERED-PRINCIPAL REGISTER
- 18 Aug 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 18 Aug 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 18 Aug 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 17 Aug 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 17 Aug 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 11 Aug 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 28 Jul 2026 — USE AMENDMENT FILED
- 11 Aug 2026 — DIVISIONAL PROCESSING COMPLETE
- 29 Jul 2026 — DIVISIONAL REQUEST RECEIVED
- 28 Jul 2026 — TEAS REQUEST TO DIVIDE RECEIVED
- 28 Jul 2026 — TEAS STATEMENT OF USE RECEIVED
- 26 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Feb 2026 — SOU EXTENSION 3 GRANTED